Statement on the Joint Action 3 Prolongation
EUnetHTA Joint Action 3 has received official approval from Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) for an extension of an additional 12 months without additional funding. This prolongation is meant to allow the finalisation of outstanding deliverables and, where possible, further prepare for a future European HTA system. The Executive Board is currently […]
EUnetHTA 2020 Assembly – Welcome Guide now available
The annual EUnetHTA Assembly aims to provide an overview into the year’s activity, while stimulating discussion on HTA-related topics and looking to the network’s next steps and future developments. Due to current events, we will be holding the 1st April Assembly online with network members, while this year’s Forum is postponed till a later date. […]
EUnetHTA Response to COVID-19
We all are faced with an unprecedented situation, a reminder of how fragile we as individuals are, how fragile our societies remain. EUnetHTA is a network of specialists, dedicated in their own jurisdictions to excellence and the support of their individual health care systems. EUnetHTA derives its strength from its diversity, from the ability to […]
PTJA09 – Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)
This is the pharmaceutical Joint Assessment PTJA09 on brolucizumab. In February 2020, the European Commission granted marketing authorisation for Beovu® (brolucizumab) for the treatment of adults with neovascular (wet) AMD. This Joint Assessment aims to compare the clinical effectiveness and safety of brolucizumab in the target patient population with relevant comparators according to the national […]
EUnetHTA releases a new guidance document that supports health technology assessments: “Practical considerations when critically assessing economic evaluations”
The aim of this guidance document is to pass on some knowledge and know-how to all stakeholders with an interest in economic evaluations by providing an overview of important points for consideration when performing/assessing such evaluations, supported by a selection of real-world examples. About this document: Authoring team: Mattias Neyt (KCE, Belgium); Martin Eriksson (SBU, […]
Statement from the EUnetHTA Secretariat on COVID-19
Due to the developing COVID-19 scenario affecting Europe and with regard to the policy responses emerging on a per national basis from certain areas, the EUnetHTA Secretariat is implementing precautionary changes to its planned 2020 events schedule. This is following instructions from the Executive Board of the Dutch National Healthcare Institute (ZIN) to revise plans […]
1st Collaborative Assessment – Wearable cardioverter-defibrillator (WCD) therapy in primary and secondary prevention of sudden cardiac arrest in patients at risk
Sudden cardiac arrest (SCA) is the most common cause of death in patients with coronary artery disease. Mostly, ventricular tachycardia and ventricular fibrillation are the underlying aetiology of SCA, which is claimed to be successfully treated by a novel defibrillation therapy, a wearable cardioverter defibrillator (WCD). The assessment aimed to provide valid data on clinical […]
PTJA08 – Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity
This is the pharmaceutical Joint Assessment PTJA08 – on siponimod for the treatment of active SPMS. In January 2020, the European Commission granted marketing authorisation for Mayzent® (siponimod) for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. This Joint Assessment […]
PTJA06 – Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant
This is the pharmaceutical Joint Assessment PTJA06 – on polatuzumab vedotin for the treatment of relapsed/refractory DLBCL. In January 2020, The European Commission granted conditional marketing authorisation for Polivy® (polatuzumab vedotin), in combination with bendamustine plus MabThera® (rituximab) (BR), for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) […]
EUnetHTA Magazine – Winter 2020 – Now Available
We are pleased to publish the Winter 2020 issue of EUnetHTA Magazine, our quarterly update on HTA with input from network stakeholders. As always, we welcome your feedback so we can continue to improve how we can focus on developments in HTA. Happy reading! Click here for more.
